Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression
Latest Information Update: 29 Mar 2024
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary) ; Anastrozole; Fulvestrant; Letrozole
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms InTTercePT; UCBG/GINECO study
- 29 Mar 2024 Last checked against European Clinical Trials Database.
- 21 Sep 2023 Planned End Date changed from 30 Jun 2025 to 30 Mar 2026.
- 21 Sep 2023 Planned primary completion date changed from 30 Dec 2024 to 30 Mar 2025.